Nautilus Biotechnology SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

10-QOct. 27, 2026, 7:37 a.m. ETView on SEC.gov
8-KOct. 26, 2026, 6:46 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedNautilus Biotechnology Q3 2026 Net Loss Widens to $15.6 Million on $0.2 Million Revenue
424B5Sept. 18, 2026, 4:35 p.m. ETView on SEC.gov
8-KSept. 11, 2026, 4:08 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Termination of a material definitive agreement · Financial statements and exhibits
SCHEDULE 13D/ASept. 11, 2026, 5:08 p.m. ETView on SEC.gov
SCHEDULE 13D/AAug. 28, 2026, 7:43 p.m. ETView on SEC.gov
SCHEDULE 13D/AAug. 14, 2026, 5:20 p.m. ETView on SEC.gov
10-QJuly 28, 2026, 4:06 p.m. ETView on SEC.gov
8-KJuly 27, 2026, 7:29 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits